This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences practice is dedicated to providing tailored solutions to help maximize value and drive towards equitable access to life-saving treatments.
Considering that cardiovascular disease (CVD) remains the leading cause of death in the United States, particularly affecting the growing population of...
CRA recently hosted a webinar with leading European payer experts to discuss the increasingly competitive rare disease (RD) landscape
